Rennova Health (RNVA) 10-Q2014 Q2 Quarterly report

Filed: 14 Nov 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: accurately, addressed, advertising, app, appending, arose, aware, background, biology, channel, collaborative, color, conduct, confusion, contributor, curation, disallowance, disproportionately, distinctly, Finder, garner, gave, GVA, increasingly, labeled, language, link, lung, MedPage, NGS, oriented, Pfizer, placement, professional, quality, recognizable, reliable, resource, revise, searchable, solidify, spectrum, straightforward, title, today, tool, understand, undertook, Variant, version

Removed: collection, customized, dividend, dynamically, expiring, factor, knowledgebase, margin, mobile, narrative, reviewing, statistical, user

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RNVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CollabRx, Inc., a Delaware corporation (the “Company“), on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission (the “Report“), I, Thomas R. Mika, President and Chief Executive Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Thomas R. Mika
President and Chief Executive Officer
November 14, 2013

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CollabRx, Inc., a Delaware corporation (the “Company“), on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission (the “Report“), I, Thomas R. Mika, Acting Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Thomas R. Mika
Acting Chief Financial Officer
November 14, 2013

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.